Komori
OncoTherapy Science (4564) · InitiativeAchieved

Reducing the burden of the pro forma standard taxation through a capital reduction without consideration and limiting cash outflows

First written in FY2017. 5 of 8 entries say "Achieved", first in FY2018-Q2. Latest entry: FY2026.

8entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2018-Q2 – FY20262017: 220172018: 020182019: 020192020: 220202021: 020212022: 020222023: 020232024: 220242025: 120252026: 12026
Same theme, other companies
Transfer to Other Capital Surplus Through Capital Reduction and Capital Structure ReorganizationA theme 203 companies write about · 0 as a headwind · 186 as a tailwind

118 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 206 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AchievedAnnual report

    「Based on the resolution of the Extraordinary General Meeting of Shareholders held on 13 February 2026, the company transferred ¥1,161,435,000 to other capital surplus as of 27 March 2026.」

    The capital reduction without compensation was implemented on 27 March 2026, reducing capital by ¥1,161,435,000 and transferring the amount to other capital surplus. Capital after the reduction was ¥50,000,000.
  2. FY2025AchievedAnnual report

    「Based on the resolution of the Extraordinary General Meeting of Shareholders held on 14 February 2025, the company transferred ¥597,141,000 to other capital surplus as of 28 March 2025.」

    The capital reduction without compensation was implemented on 28 March 2025, reducing capital by ¥597,141,000 and transferring the amount to other capital surplus. Capital after the reduction was ¥50,000,000.
  3. FY2024AchievedAnnual report

    「Based on the resolution of the Extraordinary General Meeting of Shareholders held on 14 February 2024, the company transferred ¥1,133,814,330 to other capital surplus as of 26 March 2024.」

    The capital reduction without compensation was implemented on 26 March 2024, reducing capital by ¥1,133,814,330 and transferring the amount to other capital surplus. Capital after the reduction was ¥50,000,000.
  4. FY2024-Q3AdvancedAnnual report

    「The company will reduce its capital by ¥1,133,814,330 and transfer the amount to other capital surplus, leaving capital of ¥50,000,000 after the reduction.」

    To secure flexibility and agility in its capital policy, the company resolved on a capital reduction without compensation, reducing capital by ¥1,133,814,330 to ¥50,000,000, subject to approval at the Extraordinary General Meeting of Shareholders scheduled for 14 February 2024.
  5. FY2021-Q2AchievedAnnual report

    「Based on the resolution of the Annual General Meeting of Shareholders held on 24 June 2020, the company reduced its capital by ¥1,370,486 thousand and transferred the same amount to other capital surplus as of 31 August 2020.」

    The capital reduction without compensation approved in May 2020 was implemented, reducing capital by ¥1,370,486 thousand and transferring the amount to other capital surplus.
  6. FY2020AdvancedAnnual report

    「The reduction in the amount of capital will enable the company to benefit from tax advantages, including a lower enterprise-size tax burden from the current fiscal year onward, and to curb cash outflows from the company. Of the ¥1,420,486 thousand in capital as of 31 March 2020, ¥1,370,486 thousand」

    With the approval of the Board of Directors' resolution on 22 May 2020 and the shareholders' meeting on 24 June 2020, a capital reduction without compensation was approved to reduce capital by ¥1,370,486 thousand and transfer the amount to other capital surplus. The effective date was scheduled for 31 August 2020.
  7. FY2018-Q2AchievedAnnual report

    「Based on the resolution of the 16th Annual General Meeting of Shareholders held on 20 June 2017, the company reduced its capital by ¥9,085,118 thousand and transferred the amount to other capital surplus as of 31 August 2017.」

    The planned capital reduction without compensation was implemented, with ¥9,085,118 thousand of capital reduced and transferred to other capital surplus.
  8. FY2017First statedAnnual report

    「The reduction in the amount of capital will enable the company to benefit from tax advantages, including a lower enterprise-size tax burden from the current fiscal year onward, and to curb cash outflows from the company.」

    Following the resolution of the Board of Directors on 24 May 2017 and shareholder approval on 20 June 2017, the company planned a capital reduction without compensation, transferring ¥9,085,118 thousand of capital to other capital surplus. The stated objectives were to reduce the tax burden and curb cash outflows.
Moved together

"Establishment of Cancer Precision Medicine (CPM) and expansion of genomic analysis and cancer immunology businesses through a joint venture with TE" moved the same way as this thread, in the same document, in 7 of its 8 moves.

754433★123456
  1. ★This thread
  2. 1Establishment of Cancer Precision Medicine (CPM) and expansion of genomic analysis and cancer immunology businesses through a joint venture with TE7×
  3. 2Securing and utilizing the patent portfolio5×
  4. 3Significant expansion of revenue and profit through drug launches and stabilization of the revenue base4×
  5. 4Dependence on the progress of specific pharmaceutical companies and partners4×
  6. 5Pressure on results from substantial R&D expenses and an R&D-led business model3×
  7. 6Raising R&D funds through a third-party allotment of stock acquisition rights3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reducing the burden of the pro forma standard taxation through a capital reduction without consideration and limiting cash outflows | OncoTherapy Science,Inc. (4564) | Komori